TABLE 1.
Baseline characteristics of the study subjects
| Variable | CHIC group (n = 29) | Control group (n = 58) | p |
|---|---|---|---|
| Female sex (n, %) | 16 (55.2) | 28 (48.3) | .54 |
| Age at the time of CRT implantation, mean (years) | 66.3 ± 13.8 | 67.4 ± 11.3 | .36 |
| QRS duration, mean (ms) | 146 ± 26 | 154 ± 26 | .11 |
| Baseline LVESD, mean (mm) | 52 ± 8 | 54 ± 10 | .13 |
| Baseline LVEDD, mean (mm) | 60 ± 8 | 63 ± 9 | .10 |
| Baseline LVEF, mean (%) | 28 ± 8 | 28 ± 7 | .54 |
| Type of conduction abnormality, LBBB (n,%) | 16 (55.2) | 25 (43.1) | .29 |
| Hypertension (n,%) | 10 (34.5) | 24 (41.4) | .53 |
| Diabetes mellitus (n,%) | 4 (13.8) | 12 (20.7) | .43 |
| Atrial fibrillation (n,%) | 11 (37.9) | 31 (53.5) | .17 |
| Beta-blocker use (n,%) | 27 (93.1) | 54 (93.1) | 1.00 |
| Angiotensin-converting enzyme inhibitor use (n, %) | 23 (79.3) | 41 (70.7) | .39 |
| Spironolactone use (n, %) | 7 (24.1) | 14 (24.1) | 1.00 |
| Nitrate use (n,%) | 2 (6.9) | 1 (1.7) | .21 |
| Hydralazine use (n, %) | 1 (3.5) | 1 (1.72) | .61 |
| Diuretic use (n,%) | 17 (58.6) | 47 (81.0) | .025 |
| Digoxin use (n,%) | 12 (41.4) | 8 (13.8) | .004 |
Abbreviations: CHIC, chemotherapy-induced cardiomyopathy; CRT, cardiac resynchronization therapy; LVESD, left ventricular end systolic diameter; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LBBB, left bundle branch block.